Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
China's Fosun Pharma eyes spin-off Hong Kong IPO of vaccine unit
The board of Shanghai Fosun Pharmaceutical approved the spin-off and Hong Kong listing of its vaccine unit, aiming to bolster the business as biotechnology shares continue to outperform in the city's stock market. The board cleared the proposed…
Vertex Pharma upgraded at RBC Capital Markets (VRTX:NASDAQ)
RBC Capital Markets on Thursday upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Sector Perform, arguing that the Boston, Massachusetts-based biotech is poised to record upside in 2026 on the back of a cystic fibrosis franchise that…
Hudson pharma acquired by global investment firm
Proveris Scientific, a Hudson-based pharmaceutical product development firm, has been acquired by a subsidiary of Investindustrial, an international investment group with a U.S. office in New York City. Founded in 1995, Proveris provides testing…
Sun Pharma gets regulatory approval for generic semaglutide in India
Sun Pharmaceutical has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection, the company said, as it joins domestic drugmakers lining up to launch in India and…
Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - Here's Why
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s share price gapped up before the market opened on Thursday. The stock had previously closed at $63.00, but opened at $67.90. Zealand Pharma A/S shares last traded at $67.90, with a volume of…
Pharmalittle: We're reading about Europe's pharma supply chain, stopping GLP-1 drugs, and more
Good morning, everyone, and welcome to the middle of the holiday-shortened week on this side of the pond. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After…
Ascendis Pharma A/S (NASDAQ:ASND) Hits New 12-Month High - Time to Buy?
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) reached a new 52-week high on Thursday. The company traded as high as $236.25 and last traded at $226.78, with a volume of 669088 shares. The stock had previously closed at $216.66. Get Ascendis…
BridgeBio Pharma, Inc. $BBIO Shares Sold by Emerald Advisers LLC
Emerald Advisers LLC lessened its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 29.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 720,343 shares…
Recursion Pharma at JPM26
Recursion Pharma presented at JP Morgan Healthcare 2026 and these are our highlights from their presentation. Recursion (RXRX) makes medicines out of a unified, AI-native intelligence platform that decodes complex science to find new gene targets…
US Futures, Global Markets Rally After Trump Greenland Pivot
US equity futures and global stocks are sharply higher as the S&P again marches toward a new ATH while the latest vol spike subsides, after Trump's tariff pivot eased geopolitical fears, though Greenland and other flashpoints mean the optimistic…
Vanguards of Health Care: Sofinnova Partners Betting on Data
“Despite all the noise — tariffs, regulation, geopolitics — the fundamentals are amazing, because our companies save people's lives and the demand for innovation is absolutely real.” says Antoine Papiernik, Sofinnova…
EWL: February Could Be Quite Big For Swiss Macro (NYSEARCA:EWL)
The iShares MSCI Switzerland ETF is heavily weighted toward healthcare and financials, with some exposure to tariff negotiations, which may be more than halved. Novartis faces considerable direct tariff risk but expects mitigation by mid-2026 as…
Trading ideas: AirAsia X, Mega First, F&N, Mah Sing, NationGate, DXN, Capital A, Apex Healthcare, Lim Seong Hai, Southern Score, Mulpha, Kimlun, BWYS, Cabnet, Komark, Sentral REIT, Alpha IVF
Corporate News KUALA LUMPUR: Here is a recap of the announcements that made headlines in Corporate Malaysia. AirAsia X Bhd targets US$500.0mn to US$600mn in debt restructuring after the budget airline this week bought the short-haul aviation…
Amgen: A Buy In 2026 On Exciting MariTide Obesity - T2D Potential (NASDAQ:AMGN)
Amgen Inc. is rated a Buy, driven by robust pipeline prospects and the transformative potential of its obesity drug candidate MariTide. Recent AMGN performance includes 12% revenue growth in Q3 2025, upwardly revised 2025 guidance, and healthy…
'If firms can't sell, invest in US, then there's UK; India biggest priority for Britain'
What do you think about US tariffs on India and the UK? What does it mean for India-UK trade? What happens when the US doesn't play by the rules? That is for the US to decide. There is nothing for the UK to comment on US tariff policy. The UK-India…
Receive a Daily briefing on Pharma Industry News
Get Started